- Home
- BSVN vs AUTL Comparison
BSVN vs AUTL Comparison
Compare BSVN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSVN
- AUTL
- Stock Information
- Founded
- BSVN 2004
- AUTL 2014
- Country
- BSVN United States
- AUTL United Kingdom
- Employees
- BSVN N/A
- AUTL N/A
- Industry
- BSVN Major Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSVN Finance
- AUTL Health Care
- Exchange
- BSVN Nasdaq
- AUTL Nasdaq
- Market Cap
- BSVN 335.6M
- AUTL 359.3M
- IPO Year
- BSVN 2018
- AUTL 2018
- Fundamental
- Price
- BSVN $38.34
- AUTL $2.26
- Analyst Decision
- BSVN Buy
- AUTL Strong Buy
- Analyst Count
- BSVN 2
- AUTL 5
- Target Price
- BSVN $51.00
- AUTL $9.32
- AVG Volume (30 Days)
- BSVN 21.3K
- AUTL 2.6M
- Earning Date
- BSVN 07-10-2025
- AUTL 05-08-2025
- Dividend Yield
- BSVN 2.49%
- AUTL N/A
- EPS Growth
- BSVN 46.15
- AUTL N/A
- EPS
- BSVN 4.71
- AUTL N/A
- Revenue
- BSVN $96,026,000.00
- AUTL $9,011,000.00
- Revenue This Year
- BSVN N/A
- AUTL $329.53
- Revenue Next Year
- BSVN $3.53
- AUTL $191.73
- P/E Ratio
- BSVN $8.22
- AUTL N/A
- Revenue Growth
- BSVN 28.97
- AUTL N/A
- 52 Week Low
- BSVN $27.84
- AUTL $1.11
- 52 Week High
- BSVN $50.26
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- BSVN 51.40
- AUTL 80.26
- Support Level
- BSVN $36.91
- AUTL $1.19
- Resistance Level
- BSVN $39.68
- AUTL $1.79
- Average True Range (ATR)
- BSVN 1.06
- AUTL 0.13
- MACD
- BSVN -0.00
- AUTL 0.08
- Stochastic Oscillator
- BSVN 56.31
- AUTL 98.98
About BSVN Bank7 Corp. Common stock
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.